Key result
TAVR with a self-expanding valve successfully excludes congenital P-MAIVF coexisting with severe aortic stenosis.
Why the study?
Treatment of pseudoaneurysm of the mitral-aortic intervalvular fibrosa (P-MAIVF) is debated, with complex surgery as first choice soon after diagnosis.
Does TAVR with a self-expanding valve safely exclude P-MAIVF and treat coexisting aortic stenosis?
Case Report
Does TAVR with a self-expanding valve safely exclude P-MAIVF and treat coexisting aortic stenosis?
Answers are grounded in this paper and cite their sources.
TAVR with a self-expanding valve may offer a feasible, less invasive alternative to complex surgery for treating coexisting P-MAIVF and aortic stenosis.
Pseudoaneurysm of the mitral-aortic intervalvular fibrosa (P-MAIVF) is a rare condition usually acquired as previous heart surgery or endocarditis sequela. P-MAIVF can cause life-threatening complications whose treatment is currently debated, with complex surgical interventions as first choice soon after diagnosis. Trans-catheter aortic valve replacement (TAVR) with self-expanding valve (SEV) proved to be a feasible strategy to exclude a congenital P-MAIVF coexisting with a symptomatic low-flow/low-gradient (LFLG) aortic stenosis. A recapturable SEV, implanted under trans-esophageal echocardiography (TEE) guidance, can reduce the risk of valve displacement and of P-MAIVF perforation that is probably higher in balloon-expandable (BEV) implantations.
No takes yet. Share an insight, caveat, or question.
Tondo et al. (2025) conducted a case report in Pseudoaneurysm of the mitral-aortic intervalvular fibrosa (P-MAIVF) and aortic stenosis. Trans-catheter aortic valve replacement (TAVR) with self-expanding valve (SEV) was evaluated. Transcatheter aortic valve replacement with a self-expanding valve proved to be a feasible strategy to exclude a congenital P-MAIVF coexisting with symptomatic aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: